Axsome Therapeutics, Inc. (AXSM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $204.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation.
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved commercial products: AUVELITY (MDD), SUNOSI (EDS), and SYMBRAVO (migraine), generating $638.5M in 2025 revenues (66% annual growth). The pipeline is led by... Read more
Sell if holding. Engine safety override at $204.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 4/6 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 3d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAUVELITY, SUNOSI, and SYMBRAVO10-K Item 1A: 'We are substantially dependent on the success of our products ... Apart from AUVELITY, SUNOSI, and SYMBRAVO, we have no other products which have received regulatory approval.'
- MEDIUMpipelineAXS-05 for AD agitation10-K Item 1A: 'Breakthrough Therapy designation by the FDA for AXS-05 for the treatment of AD agitation'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $204.51: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $193.21. Score 5.6/10, moderate confidence.
Take-profit target: $212.66 (+2.4% upside). Prior stop was $193.21. Stop-loss: $193.21.
Concentration risk — Product: AUVELITY, SUNOSI, and SYMBRAVO; Target reached (-3.0% upside); Quality below floor (4.0 < 4.0).
Axsome Therapeutics, Inc. trades at a P/E of N/A (forward 36.5). TrendMatrix value score: 3.4/10. Verdict: Sell.
26 analysts cover AXSM with a consensus score of 4.3/5. Average price target: $224.
What does Axsome Therapeutics, Inc. do?Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved...
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved commercial products: AUVELITY (MDD), SUNOSI (EDS), and SYMBRAVO (migraine), generating $638.5M in 2025 revenues (66% annual growth). The pipeline is led by AXS-05 for Alzheimer's disease agitation, with FDA Priority Review and a PDUFA date of April 30, 2026.